NPPA Fixes Retail Price Of 18 Formulations, Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed retail prices of 18 formulations.
This came in line with the decision of 108 th authority meeting dated 27.01.2023, where the Authority discussed new drug applications for price fixation under para 5 and para 15 of DPCO 2013.
The new drugs which retail prices were fixed include Akums Drugs & Pharmaceuticals, Cadila Pharma's Domperidone and Naproxen Sodium Tablets, Pharma Force Lab, Mankind Pharma's Calcium, Phosphorus, Magnesium, Zinc & Vitamin D3 Suspension, Olive Healthcare, Intas Pharmaceutical's fixed dose combination drug Methylcobalamin, Alpha Lipoic Acid, Inositol, Folic Acid, Chromium Polynicotinate, Selenium Dioxide & Benfotiamine Capsule, Ravenbhel Healthcare, IPCA Laboratories Itraconazole Cpasule (SupraBioavailable Formulation).
The list further includes Ferrous Ascorbate, Folic Acid & Methylcobalam in Suspension manufactured and marketed by Akums Drugs & Pharmaceuticals and Cipla respectively, Paracetamol & Mefenamic Acid Suspension manufactured and marketed by Prosperity Drugs and Torrent Pharmaceuticals respectively, Diclofenac Sodium and Paracetamol Tablets manufactured and marketed by Akums Drugs & Pharmaceuticals and Emcure Pharmaceuticals.
This comes after in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority , has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3),(4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Rosuvastatin and Clopidogrel Capsule | Each Hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) | 1 Capsule | M/s Synokem Pharmaceuticals Ltd. / M/s Zydus Healthcare Limited | 19.04 |
2 | Domperidone and Naproxen Sodium Tablets | Each film coated tablet contains: Domperidone Maleate IP eq. to Domperidone 10mg Naproxen Sodium USP 550mg eq. to Naproxen 500mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cadila Pharmaceuticals Ltd. | 6.99 |
3 | Domperidone and Naproxen Sodium Tablets | Each film coated tablet contains: Domperidone Maleate IP eq. to Domperidone 10mg Naproxen Sodium USP 275mg eq. to Naproxen 250mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cadila Pharmaceuticals Ltd. | 5.39 |
4 | Rosuvastatin, Clopidogrel & Aspirin Capsule | Each Hard gelatin capsule cotains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg Aspirin IP 75mg | 1 Capsule | M/s Windlas Biotech Limited. / M/s Modi- Mundipharma Pvt. Ltd. | 14.48 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
5 | Calcium, Phosphorus, Magnesium, Zinc & Vitamin D3 Suspension | Each 10ml contains: Calcium Phosphate IP eq. to Elemental Calcium 300mg eq. to Elemental Phosphorus 150mg Magnesium Hydroxide IP eq. to Elemental Magnesium 75mg Zinc Gluconate USP eq. to Elemntal Zinc 4mg Vitamin D3 IP 200IU | 1 ml | M/s Pharma Force Lab. / M/s Mankind Pharma Ltd. | 0.68 |
6 | Phenylephrine Hydrochloride, Chlorpheniram ine Maleate, Paracetamol, Sodium Citrate & Menthol Suspension | Each 5ml contains: Phenylephrine Hydrochloride IP 5mg Chlorpheniramine Maleate IP 0.5mg Paracetamol IP 125mg Sodium Citrate IP 60mg Menthol IP 1mg | 1 ml | M/s Bioconic Remedies / M/s Dales Laboratories Pvt. Ltd. | 0.87 |
7 | Methylcobalam in, Alpha Lipoic Acid, Inositol, Folic Acid, Chromium Polynicotinate, Selenium Dioxide & Benfotiamine Capsule | Each soft Gelatin Capsule contains: Methylcobalamin IP 1500mcg Alpha Lipoic Acid USP 100mg Inositol USP NF 100mg Folic Acid IP 1.5mg Chromium Polynicotinate 200mcg Selenium Dioxide USP 55mcg Benfotiamine 150mg | 1 Capsule | M/s Olive Healthcare / M/s Intas Pharmaceuticals Limited | 18.56 |
8 | Itraconazole Cpasule (Supra- Bioavailable Formulation) | Each hard gelatin capsule contains: Itraconazole BP 65mg | 1 Capsule | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s IPCA Laboratories Limited | 11.60 |
9 | Itraconazole Cpasule (Supra- Bioavailable Formulation) | Each hard gelatin capsule contains: Itraconazole BP 130mg | 1 Capsule | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s IPCA Laboratories Limited | 20.72 |
10 | Rosuvastatin, Aspirin and Clopidogrel Capsule | Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (as film coated tablet) Aspirin IP 75mg (As Gastro- resistant tablet) Clopidogrel Bisulphate eq. to Clopidogrel IP 75 mg (as film coated tablet) | 1 Capsule | M/s Akums Drugs and Pharmaceuticals Ltd. / M/s Cadila Pharmaceuticals Ltd. | 14.48 |
11 | Rosuvastatin, Aspirin and | Each hard gelatin capsule contains: | 1 Capsule | M/s Akums Drugs and | 20.69 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Clopidogrel Capsule | Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (as film coated tablet) Aspirin IP 75mg (As Gastro- resistant tablet) Clopidogrel Bisulphate eq. to Clopidogrel IP 75 mg (as film coated tablet) | Pharmaceuticals Ltd. / M/s Cadila Pharmaceuticals Ltd. | |||
12 | Ferrous Ascorbate, Folic Acid & Methylcobalam in Suspension | Each 5ml contains: Ferrous Ascorbate IP eq. to Elemental Iron 30mg Folic Acid IP 500mg Methyl cobalamin IP 500mcg | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Limited | 0.92 |
13 | Doxorubicin Hydrochloride Liposomal Injection (Pegylated liposomal) | Each ml Contains: Doxorubicin Hydrochloride (as pegylated liposomal) IP 2mg water for injection | 1 ml | M/s Samarth Life Sciences Pvt. Ltd. | 452.45 |
14 | Diclofenac Sodium & Dicyclomine Hydrochloride Injection | Each ml contains: Diclofenac Sodium IP 50mg Dicyclomine Hydrochloride IP 20mg Benzalkonium Chloride Solution IP 0.05% w/v Water for Injections IP q. s. | 1 ml | M/s Nichepharm Lifesciences Pvt. Ltd. / M/s Seagull Pharmaceuticals Pvt, Ltd. | 31.08 |
15 | Paracetamol & Mefenamic Acid Suspension | Each 5ml contains: Paracetamol IP 250mg Mefenamic Acid IP 100mg | 1 ml | M/s Prosperity Drugs Pvt. Ltd. / M/s Torrent Pharmaceuticals Limited | 0.75 |
16 | Paracetamol & Mefenamic Acid Suspension | Each 5ml contains: Paracetamol IP 125mg Mefenamic Acid IP 50mg | 1 ml | M/s Prosperity Drugs Pvt. Ltd. / M/s Torrent Pharmaceuticals Limited | 0.65 |
17 | Cefixime and Potassium Clavulanate Tablets IP | Each film coated tablet contains: Cefixime Trihydrate eq. to Cefixime Anhydrous IP 200mg Potassium Clavulanate Diluted eq. to Clavulanic Acid IP 125mg | 1 Tablet | M/s Alps Communications Pvt. Ltd. / M/s Aristo Laboratories Pvt. Ltd. | 24.00 |
18 | Diclofenac Sodium and Paracetamol Tablets | Each uncoated tablet contains: Diclofenac Sodium IP 50mg, Paracetamol IP 325mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Ltd. | 4.20 |
The notification further added,
(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
